Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company that operates a growing contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement, which expands an existing customer relationship, includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms.
The engagement covers development and clinical manufacturing services for an investigational oncology product, with revenue expected during 2026 and 2027 and stability services extending beyond 2027. Following the agreement, Scinai’s committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million, up 300% from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones.
The deal underscores the growing demand for reliable CDMO services in the oncology space and highlights Scinai’s expanding role as a manufacturing partner for biotechnology and pharmaceutical companies. For investors, the 300% jump in committed orders signals strong commercial momentum and revenue visibility, while the potential additional $5.85 million in uncommitted opportunities could provide further upside if milestones are met. For the broader biopharma industry, the agreement reflects continued outsourcing of development and manufacturing by Nasdaq-listed companies, a trend that benefits specialized CDMOs like Scinai.
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is focused on the development of innovative immunology therapies and is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services through facilities in Jerusalem and Yavne, Israel. To view the full press release, visit https://ibn.fm/5jaNp. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
The announcement was distributed through MissionIR, a specialized communications platform that assists IR firms with syndicated content. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions of followers.
For more information, visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
